Item 7.01 Regulation FD Disclosure.
On January 20, 2021, Ocular Therapeutix, Inc. (the "Company") announced its
intent to present interim data at the Glaucoma 360 Conference from the Company's
ongoing multi-center, open-label, dose-escalation, proof-of-concept Phase 1
clinical trial of product candidate OTX-TIC compared to topical travoprost eye
drops in patients with primary open-angle glaucoma or ocular hypertension.
OTX-TIC is a bioresorbable hydrogel implant incorporating travoprost that is
designed to be administered by a physician as an intracameral injection with an
initial target duration of drug release of four to six months. Information to be
provided during such presentation is being furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1
hereto, shall not be deemed to be "filed" for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise
subject to the liabilities of such section, nor will such information be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as may be expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Ocular Therapeutix, Inc. slide presentation, dated January
99.1 2021
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document)
© Edgar Online, source Glimpses